PMID- 12793903
OWN - NLM
STAT- MEDLINE
DCOM- 20030627
LR  - 20231103
IS  - 1465-542X (Electronic)
IS  - 1465-5411 (Print)
IS  - 1465-5411 (Linking)
VI  - 5
IP  - 3
DP  - 2003
TI  - Detection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary 
      drainage after operations for breast cancer using reverse 
      transcriptase-polymerase chain reaction.
PG  - R71-6
AB  - BACKGROUND: The diverse biological effects of hepatocyte growth factor/scatter 
      factor (HGF/SF) are mediated by c-Met, which is preferentially expressed on 
      epithelial cells. Met signaling has a role in normal cellular activities, and may 
      be associated with the development and progression of malignant processes. In 
      this study we examined whether Met can be detected in the axillary drainage from 
      patients who underwent conservative operations for breast cancer, and its 
      prognostic significance. METHODS: Thirty-one consecutive patients with invasive 
      ductal carcinoma of the breast suitable for breast-conserving treatment were 
      studied. The output of the drain that had been placed in the axilla during the 
      operation was collected, and the presence of Met and beta-actin were assessed by 
      reverse transcriptase-polymerase chain reaction (RT-PCR) assays. The data were 
      compared with the pathological features of the tumor and the axillary lymph 
      nodes, and with the estrogen receptor and progesterone receptor status. RESULTS: 
      RT-PCR of the axillary lymphatic drainage was positive for Met in 23 (74.2%) of 
      the patients. Positive assays were correlated with increasing tumor size and 
      grade, with capillary and lymphatic invasion, and with lymph node metastasis (P < 
      0.02, for all comparisons). All 12 patients with axillary lymph node metastases 
      had positive assays for Met, compared with 57.9% of patients without lymph node 
      metastases. All five patients with tumor involvement in the margins of the 
      resection had positive assays for Met in their lymphatic fluid, compared with 18 
      of 26 positive assays (69.2%) for patients without involved margins (P < 0.04). 
      Finally, Met showed negative correlations with positivity for estrogen receptor 
      and progesterone receptor (P < 0.02). CONCLUSION: Met can be detected in the 
      axillary fluids of patients with breast cancer and its expression in the axillary 
      drainage may have potential as a prognostic factor. This finding might be 
      relevant to therapeutic considerations, because a positive assay for Met in 
      histologically node-negative patients might point to the need to search for node 
      microinvasion or involvement of the excision margins with tumor.
FAU - Greenberg, Ron
AU  - Greenberg R
AD  - Department of Surgery A, Tel-Aviv Medical Center, Tel-Aviv University, Tel-Aviv, 
      Israel. rongree@mailcity.com
FAU - Schwartz, Ignat
AU  - Schwartz I
FAU - Skornick, Yehuda
AU  - Skornick Y
FAU - Kaplan, Ofer
AU  - Kaplan O
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20030306
PL  - England
TA  - Breast Cancer Res
JT  - Breast cancer research : BCR
JID - 100927353
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Axilla/*pathology/surgery
MH  - Biomarkers, Tumor/biosynthesis/genetics
MH  - Breast Neoplasms/genetics/*pathology/surgery
MH  - Carcinoma, Ductal, Breast/*pathology/secondary/surgery
MH  - *Drainage
MH  - Exudates and Transudates/chemistry
MH  - Female
MH  - Humans
MH  - Lymph Nodes/pathology/surgery
MH  - Lymphatic Metastasis/genetics/pathology
MH  - Middle Aged
MH  - Neoplasm Invasiveness/genetics/pathology
MH  - Proto-Oncogene Proteins c-met/*biosynthesis/genetics
MH  - RNA, Messenger/biosynthesis
MH  - Receptors, Estrogen/biosynthesis
MH  - Receptors, Progesterone/biosynthesis
MH  - Reverse Transcriptase Polymerase Chain Reaction/*methods
PMC - PMC165003
EDAT- 2003/06/10 05:00
MHDA- 2003/06/28 05:00
PMCR- 2003/03/06
CRDT- 2003/06/10 05:00
PHST- 2002/10/21 00:00 [received]
PHST- 2003/01/09 00:00 [revised]
PHST- 2003/02/04 00:00 [accepted]
PHST- 2003/06/10 05:00 [pubmed]
PHST- 2003/06/28 05:00 [medline]
PHST- 2003/06/10 05:00 [entrez]
PHST- 2003/03/06 00:00 [pmc-release]
AID - bcr588 [pii]
AID - 10.1186/bcr588 [doi]
PST - ppublish
SO  - Breast Cancer Res. 2003;5(3):R71-6. doi: 10.1186/bcr588. Epub 2003 Mar 6.